亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

湖北康寶泰精細化工有限公司原料銷售部  

沒有填寫主營業務~~

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:陳小玲
  • 電話:027-87738653
  • QQ:418251814
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 索拉非尼
索拉非尼
單價 2.00 / KG對比
銷量 暫無
發貨 湖北武漢市付款后24小時內
庫存 1000000000KG起訂1KG
品牌 康寶泰
過期 長期有效
更新 2014-10-17 14:45
 
詳細信息

聯系人:陳小姐  電話:027-87738653

索拉非尼
CAS號: 284461-73-0
中文同義詞: 索拉非尼;4-{4-[3-(4-氯-3-三氟甲基苯基)酰脲]苯氧基}吡啶-2-甲酰胺;對***磺酸索拉非尼;索拉菲尼;索+E51拉尼;索拉非尼堿;索拉替尼
英文名稱: Sorafenib tosylate
英文同義詞: sorafenib;SORAFENIB-D3;SORAFENIB TOLSYLATE;RAF1 KINASE INHIBITOR II;N-(4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)-((4-(2-(N-METHYL-CARBAMOYL)(4-PYRIDYLOXY))PHENYL)AMINO)CARBOXAMIDE;4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-pyridine-2-carboxamide;BAY 43-9006;SORAFENIB MESYLATE
分子式: C21H16ClF3N4O3
分子量: 464.83
標準:企標含量;99%
用途:抗腫瘤藥
包裝:根據客戶要求包裝 


產品技術與銷售咨詢熱線:027-87738653  QQ:418251814
產品技術與銷售咨詢熱線:027-87738653  QQ:418251814
產品技術與銷售咨詢熱線:027-87738653  QQ:418251814

以上產品是原料藥,只適宜科研研究實驗,客戶對其購買的產品使用和再加工或再銷售負法律和試用風險全責!

©2025 湖北康寶泰精細化工有限公司原料銷售部 版權所有   技術支持:化工網   訪問量:1124  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |